175 related articles for article (PubMed ID: 35979216)
1. Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial.
Shah MR; Fatima S; Khan SN; Ullah S; Himani G; Wan K; Lin T; Lau JYN; Liu Q; Lam DSC
Front Med (Lausanne); 2022; 9():928468. PubMed ID: 35979216
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers.
Dong Q; Qiao H; Jiang H; Liu L; Ge Y; Zong FJ; Li Y; Dong B; Hu S; Meng D; Jin R; Wang X; Chang H; Xu X; Wang C; Cao Y; Zhang HT; Liu Q
Front Pharmacol; 2023; 14():1094089. PubMed ID: 36923353
[No Abstract] [Full Text] [Related]
4. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Jinhua Qinggan granules in the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Si X; Ma X; Wang Y; Li Y; Liu L; Yang Y; Guo Z; Liang Y; Pan G
Medicine (Baltimore); 2023 Apr; 102(15):e33545. PubMed ID: 37058020
[TBL] [Abstract][Full Text] [Related]
6. Exploration of the utility of different doses of Qingfei Dayuan granules: a multicenter, randomized, double-blind, placebo-controlled trial.
Zhu X; Li W; Yang Y; Li H; Yang M; Zhang J; Li X; Yan G; Wu X; Zhao W; Cui M; Yang X; Hu X; Huang J; Ba Y
Aging (Albany NY); 2024 Feb; 16(5):4503-4517. PubMed ID: 38412322
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of Qingfei Dayuan granules for treating influenza and upper respiratory tract infections manifested by the pulmonary heat-toxin syndrome: A multicenter, randomized, double-blind, placebo-controlled trial.
Li W; Xie L; Zhu X; Yang Y; Wang L; Yang M; Li H; Li X; Yan G; Wu X; Zhao W; Zhang J; Yang G; Guo Y; Li C; Wang R; Shi L; Xiong Z; Xu P; Kong W; Cui M; Yang X; Ba Y
Front Pharmacol; 2023; 14():1133560. PubMed ID: 37007028
[No Abstract] [Full Text] [Related]
8. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.
Zhan Y; Lin Z; Liang J; Sun R; Li Y; Lin B; Ge F; Lin L; Lu H; Su L; Xiang T; Pan H; Huang C; Deng Y; Wang F; Xu R; Chen D; Zhang P; Tong J; Wang X; Meng Q; Zheng Z; Ou S; Guo X; Yao H; Yu T; Li W; Zhang Y; Jiang M; Fang Z; Song Y; Chen R; Luo J; Kang C; Liang S; Li H; ; Zheng J; Zhong N; Yang Z
EClinicalMedicine; 2024 Jan; 67():102359. PubMed ID: 38188690
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial.
An X; Xu X; Xiao M; Min X; Lyu Y; Tian J; Ke J; Lang S; Zhang Q; Fan A; Liu B; Zhang Y; Hu Y; Zhou Y; Shao J; Li X; Lian F; Tong X
Front Med (Lausanne); 2021; 8():728055. PubMed ID: 34712679
[No Abstract] [Full Text] [Related]
11. The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis.
Zhang Q; Cao F; Wang Y; Xu X; Sun Y; Li J; Qi X; Sun S; Ji G; Song B
Medicine (Baltimore); 2020 Jun; 99(24):e20531. PubMed ID: 32541475
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials.
Liang SB; Fang M; Liang CH; Lan HD; Shen C; Yan LJ; Hu XY; Han M; Robinson N; Liu JP
Complement Ther Med; 2021 Aug; 60():102744. PubMed ID: 34091029
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
14. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.
Lu CL; Yang LQ; Jin XY; Friedemann T; Li YF; Liu XH; Chen XY; Zou XY; Zhang BR; Wang FX; Lin YL; Tang YM; Cao ML; Jiang YL; Gao YF; Liu K; Tao ZG; Robinson N; Schröder S; Liu JP; Lu HZ
Front Pharmacol; 2024; 15():1383831. PubMed ID: 38863976
[No Abstract] [Full Text] [Related]
15. Integrated network pharmacology and experimental validation-based approach to reveal the underlying mechanisms and key material basis of Jinhua Qinggan granules against acute lung injury.
Mi Y; Liang Y; Liu Y; Bai Z; Li N; Tan S; Hou Y
J Ethnopharmacol; 2024 May; 326():117920. PubMed ID: 38373663
[TBL] [Abstract][Full Text] [Related]
16. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
18. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
19. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial.
Wijewickrama A; Idampitiya D; Karunarathne M; Pahalagamage S; Sellahewa K; Govindapala D; Kalambarachchi H; Sooriyarachchi R; Chandrarathne N; Goonaratna C; Perera J
J Ethnopharmacol; 2024 Apr; 323():117535. PubMed ID: 38070837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
